Seno gets $2m in state funding:
This article was originally published in Clinica
Executive Summary
Opto-acoustic technology specialist Seno Medical Instruments has been awarded $2m from the Texas Emerging Technology Fund (TETF), a $200m government investment programme aimed at financing local advancing technology projects. This investment allows San Antonio, Texas-based Seno to further develop its breast cancer imaging technology, and work towards implementing initial clinical trials on technology at the Cancer Therapy and Research Center, and the University of Texas Health Science Center. The company is aiming to provide a device that uses optics and acoustics, instead of x-ray radiation, to capture an accurate image of a tumour.
You may also be interested in...
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.